Thursday, 30 March 2017 - 22:23

Top stories

News of the week

Ocrevus (Roche) approved for multiple sclerosis treatment

Roche today announced that FDA has granted approval to investigational therapy OCREVUS™ (ocrelizumab), developed for the treatment of primary progressive multiple sclerosis, a condition affecting approximately 15 %of the 2.3 million people with multiple sclerosis. The approval has been granted…

Approvals

Procedures / New drug and device authorizations / Recommendations

Ocrevus (Roche) approved for multiple sclerosis treatment

Roche today announced that FDA has granted approval to investigational therapy OCREVUS™ (ocrelizumab), developed for the treatment of primary progressive multiple sclerosis, a condition affecting approximately 15 %of the 2.3 million people with multiple sclerosis. The approval has been granted…

Companies

Healthcare market news

Ocrevus (Roche) approved for multiple sclerosis treatment

Roche today announced that FDA has granted approval to investigational therapy OCREVUS™ (ocrelizumab), developed for the treatment of primary progressive multiple sclerosis, a condition affecting approximately 15 %of the 2.3 million people with multiple sclerosis. The approval has been granted…

Chemistry

Market and Technology

Growing pressure on AkzoNobel CEO, shareholders press for talks with PPG

Dutch daily Het Financieele Dagblad yesterday reported that almost 25% of shareholders in Akzo Nobel asked the group board to enter into talks with US-based PPG, which has already submitted two bids to acquire all of the shares in the…

M&A

Mergers & Acquisitions

Growing pressure on AkzoNobel CEO, shareholders press for talks with PPG

Dutch daily Het Financieele Dagblad yesterday reported that almost 25% of shareholders in Akzo Nobel asked the group board to enter into talks with US-based PPG, which has already submitted two bids to acquire all of the shares in the…

Nutraceuticals

Food supplements

Vitamin D and headache, new results

Results from a study examining the link between low vitamin D and headache in men have been published on Scientific Reports. Literature includes previous research about the issue, however the available results have not allowed to formulate hypotheses to date,…

Pathology

Latest developments

Vertex impresses investors with positive data on new therapy for cystic fibrosis

Vertex Pharmaceuticals yesterday announced results from two Phase III studies – EVOLVE and EXPAND – of the investigational therapy combining tezacaftor (VX-661) with ivacaftor in people with cystic fibrosis. The data showed statistically significant improvements in lung function (ppFEV1). Based…

Safety

News on Product Safety

Here is how much a Big Pharma company like Johnson & Johnson spends in lawyers

Johnson & Johnson reported legal costs for $817m in the last 12 months –a 480% increase year-on-year. This shocking increase is due to more than 100,000 patients suing the US pharma giant for side-effects associated to some drugs. This is…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Vertex impresses investors with positive data on new therapy for cystic fibrosis

Vertex Pharmaceuticals yesterday announced results from two Phase III studies – EVOLVE and EXPAND – of the investigational therapy combining tezacaftor (VX-661) with ivacaftor in people with cystic fibrosis. The data showed statistically significant improvements in lung function (ppFEV1). Based…